InspireMD (NSPR) Q2 2024 earnings summary

Executive summary

• One-year outcomes from the pivotal C-GUARDIANS trial showed a 1.95% major event rate, the lowest for any carotid pivotal trial, supporting a patient-first, implant-driven strategy and anticipated U.S. approval in H1 2025.

• Over 55,000 CGuard devices have been sold globally, with consistent superior outcomes across studies and real-world use, positioning the product as a potential gold standard.

• U.S. commercial launch preparations are underway, including building a leadership team, establishing a headquarters in Southeast Florida, and expanding production and training capacity.

• The company is advancing its SwitchGuard Neuroprotection System and TCAR-compatible stent platform, aiming to offer a comprehensive next-generation tool set.

• Completed enrollment in the CREST-2 clinical trial and advanced preparations for the CGUARDIANS II TCAR clinical trial.

Financial highlights

• Q2 2024 revenue grew 5.4% year-over-year to $1.74 million, with 2,969 CGuard stents sold, driven by growth in existing and new markets.

• Gross profit declined 32.6% year-over-year to $331,000, with gross margin dropping to 19% from 29.8% due to higher material, labor, and scaling costs.

• Operating expenses rose 48% year-over-year to $8.59 million, mainly from increased compensation and largely non-cash share-based expenses.

• Net loss for Q2 2024 was $7.91 million ($0.22 per share), compared to $5.08 million ($0.24 per share) in Q2 2023.

• Cash, cash equivalents, and marketable securities totaled $47.2 million as of June 30, 2024, up from $39 million at year-end 2023, including $17.9 million from Series H warrant exercise.

Outlook and guidance

• PMA submission for CGuard Prime is on track for Q3 2024, with U.S. commercial launch targeted for H1 2025 pending FDA approval.

• Additional milestone-based financings could bring in up to $53.7 million upon achieving FDA approval, SwitchGuard TCAR kit clearance, and four quarters of U.S. sales.

• Operating expenses are expected to increase 30–40% in 2025 due to U.S. commercialization, clinical trials, and operational scaling.

• Management expects continued losses and negative cash flows until commercial profitability is reached; additional capital may be needed.

• CGUARDIANS II clinical trial initiation planned for the back half of 2024.